

WEDNESDAY, 14th NOVEMBER 2012 COMMENCING 10.30 AM

(UNTIL 4.00 PM APPROX)

AT [THE ANGEL HOTEL](#), ABERGAVENNY, NP7 5EN

AGENDA

Enclosure

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Chairman's report (verbal update)**
5. **Minutes of previous meeting**

1/AWMSG/1112

Appraisal 1 - 2 will be held in public. Appraisal 3 will be held in private

6. **Appraisal 1: Full Submission**
Fidaxomicin (Dificlir[®]) for the treatment of adults with Clostridium difficile infections (CDI), also known as C. difficile-associated diarrhoea (CDAD)
7. **Appraisal 2: Limited Submission**
Insulin detemir (Levemir[®]) for the treatment of diabetes mellitus in children aged 2-5 years

2/AWMSG/1112
Appendices

3/AWMSG/1112
Appendices

Proceedings held in public will close and the next part of the meeting will be held in private with representatives of the applicant pharmaceutical company in attendance. The information pertaining to agenda item 8 will not be posted on the AWMSG website

8. **Appraisal 3: Full Submission (Resubmission)**
Degarelix (Firmagon[®]) for the treatment of adult male patients with advanced hormone-dependent prostate cancer

4/AWMSG/1112
Appendices

The public will now be invited to return for the remainder of the meeting

9. **Homecare Services Sub Group**

5/AWMSG/1112

Date of next meeting:

Wednesday, 12th December 2012 in Abergavenny